Literature DB >> 23322088

hPNAS-4 inhibits proliferation through S phase arrest and apoptosis: underlying action mechanism in ovarian cancer cells.

Lei Li1, Den-bang Chen, Chao Lin, Kang Cao, Yang Wan, Xin-yu Zhao, Chun-lai Nie, Zhu Yuan, Yu-quan Wei.   

Abstract

PNAS-4, a novel pro-apoptotic gene, was activated during the early response to DNA damage. Previous studies have shown that hPNAS-4 can inhibit tumor growth when over-expressed in ovarian cancer cells. However, the underlying action mechanism remains elusive. In this work, we found that hPNAS-4 expression was significantly increased in SKOV3 cells when exposed to cisplatin, methyl methanesulfonate or mitomycin C, and that its overexpression could induce proliferation inhibition, S phase arrest and apoptosis in A2780s and SKOV3 ovarian cancer cells. The S phase arrest caused by hPNAS-4 was associated with up-regulation of p21. p21 is p53-dispensable and correlates with activation of ERK, and activation of the Cdc25A-Cdk2-Cyclin E/Cyclin A pathway, while the pro-apoptotic effects of hPNAS-4 were mediated by activation of caspase-9 and -3 other than caspase-8, and accompanied by release of AIF, Smac and cytochrome c into the cytosol. Taken together, these data suggest a new mechanism by which hPNAS-4 inhibits proliferation of ovarian cancer cells by inducing S phase arrest and apoptosis via activation of Cdc25A-Cdk2-Cyclin E/Cyclin A axis and mitochondrial dysfunction-mediated caspase-dependent and -independent apoptotic pathways. To our knowledge, we provide the first molecular evidence for the potential application of hPNAS-4 as a novel target in ovarian cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322088     DOI: 10.1007/s10495-012-0797-z

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  6 in total

1.  Antitumor activity of kielmeyera coriacea leaf constituents in experimental melanoma, tested in vitro and in vivo in syngeneic mice.

Authors:  Carlos Rogério Figueiredo; Alisson Leonardo Matsuo; Mariana Hiromi Massaoka; Natalia Girola; Ricardo Alexandre Azevedo; Aline Nogueira Rabaça; Camyla Fernandes Farias; Felipe Valença Pereira; Natalia Silva Matias; Luciana Pereira Silva; Elaine Guadelupe Rodrigues; João Henrique Guilardi Lago; Luiz Rodolpho Travassos; Regildo Márcio Gonçalves Silva
Journal:  Adv Pharm Bull       Date:  2014-08-25

2.  ERK1/2 inhibition enhances apoptosis induced by JAK2 silencing in human gastric cancer SGC7901 cells.

Authors:  Cuijuan Qian; Jun Yao; Jiji Wang; Lan Wang; Meng Xue; Tianhua Zhou; Weili Liu; Jianmin Si
Journal:  Mol Cell Biochem       Date:  2013-11-01       Impact factor: 3.396

3.  PNAS-4, an Early DNA Damage Response Gene, Induces S Phase Arrest and Apoptosis by Activating Checkpoint Kinases in Lung Cancer Cells.

Authors:  Zhu Yuan; Wenhao Guo; Jun Yang; Lei Li; Meiliang Wang; Yi Lei; Yang Wan; Xinyu Zhao; Na Luo; Ping Cheng; Xinyu Liu; Chunlai Nie; Yong Peng; Aiping Tong; Yuquan Wei
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

4.  P53-dependent downregulation of hTERT protein expression and telomerase activity induces senescence in lung cancer cells as a result of pterostilbene treatment.

Authors:  Rong-Jane Chen; Pei-Hsuan Wu; Chi-Tang Ho; Tzong-Der Way; Min-Hsiung Pan; Hsiu-Min Chen; Yuan-Soon Ho; Ying-Jan Wang
Journal:  Cell Death Dis       Date:  2017-08-10       Impact factor: 8.469

5.  The role of ROS and subsequent DNA-damage response in PUMA-induced apoptosis of ovarian cancer cells.

Authors:  Jun Yang; Xinyu Zhao; Mei Tang; Lei Li; Yi Lei; Ping Cheng; Wenhao Guo; Yu Zheng; Wei Wang; Na Luo; Yong Peng; Aiping Tong; Yuquan Wei; Chunlai Nie; Zhu Yuan
Journal:  Oncotarget       Date:  2017-04-04

6.  Combination of DESI2 and IP10 gene therapy significantly improves therapeutic efficacy against murine carcinoma.

Authors:  Chao Lin; HuaYing Yan; Jun Yang; Lei Li; Mei Tang; Xinyu Zhao; Chunlai Nie; Na Luo; Yuquan Wei; Zhu Yuan
Journal:  Oncotarget       Date:  2017-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.